OTC
WVE icon

Opera Trading Capital’s Wave Life Sciences WVE Stock Holding History

Opera Trading Capital’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,150
Closed -$58K – 165
2018
Q3 		$58K Buy
+1,150
New +$51.9K 0.01% 141

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Opera Trading Capital's WVE Position: Q4 2018 in Review

Opera Trading Capital sold out of Wave Life Sciences (WVE) in Q4 2018, closing a stake of 1,150 shares — an estimated $58K sold.

Opera Trading Capital first reported a position in WVE in Q3 2018 and held it in 1 quarter. The position peaked at $58K in Q3 2018. 92 funds tracked by Wall St. Rank hold WVE as of Q4 2018.

  • Opera Trading Capital reported no remaining Wave Life Sciences position as of Q4 2018 after selling out during the quarter.
  • Opera Trading Capital sold 1,150 Wave Life Sciences shares in Q4 2018, an estimated $58K.
  • Opera Trading Capital first reported a position in Wave Life Sciences in Q3 2018 and held it in 1 quarter.
  • Opera Trading Capital's Wave Life Sciences position peaked at $58K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Wave Life Sciences as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.